Answers are grounded in this paper and cite their sources.
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti–PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326–8.
No takes yet. Share an insight, caveat, or question.
Pérez-Ruiz et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: